Late-stage trials found that two doses of the Sanofi vaccine were about 58% effective in preventing infection and 75% effective in preventing moderate to severe disease.
Drugmakers Sanofi and GlaxoSmithKline said Wednesday they will seek regulatory approval for a new COVID-19 vaccine after human trials showed it provided a high level of protection against the disease.
“The evolving epidemiology of COVID-19 demonstrates the need for a variety of vaccines,’’ Roger Connor, president of GSK Vaccines, said in a statement. The drugmakers said they plan to seek regulatory approval from both the U.S. Food and Drug Administration and the European Medicines Agency, which regulates drugs in the European Union.
Late-stage trials of the current formulation of the vaccine were conducted on 10,000 adults in the U.S., Asia, Africa and Latin America. The companies didn’t provide a breakdown of the vaccine’s effectiveness for different age groups. Full results from the study will be published later this year.